Search ↗

Comparison

Cerebrolysin vs Semax

Both are nootropic & neuro, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, Cerebrolysin is the better documented of the two (clinical trials). That is a statement about the state of the literature, not a recommendation.

Cerebrolysin Semax
Class Nootropic & neuro Nootropic & neuro
Evidence Clinical trials Preliminary human
Human trials ~40 ~8
Half-life Not established (mixture) ~30 minutes (intranasal)
Reported range 5-30 g 300-900 mcg
Frequency Daily intravenous infusion or intramuscular injection over 10-20 day courses 1-3x daily intranasal
Routes Intravenous, Intramuscular Intranasal, Subcutaneous
FDA approved No No
Research use only Yes Yes
Banned in sport No No
Studied for Vascular dementia, Stroke recovery, Traumatic brain injury, Alzheimer's research Cognitive enhancement research, Stroke recovery, Optic nerve conditions
Reported side effects Injection-site reactions, Dizziness, Sweating, Agitation Nasal irritation, Headache, Overstimulation, Irritability

Cerebrolysin

Cerebrolysin is not a single molecule but a standardised enzymatic hydrolysate of purified porcine brain protein, containing low-molecular-weight peptides and free amino acids. It is proposed to act in a neurotrophic-like manner, supporting neuronal survival, synaptic plasticity and neurogenesis in a way that partly mimics endogenous neurotrophic factors. Clinical evidence in vascular dementia and traumatic brain injury exists and is moderately encouraging, though heterogeneity across trials is substantial.

Semax

Semax is an analog of adrenocorticotropic hormone fragment 4-10, extended with proline-glycine-proline to resist enzymatic degradation. The modification removes hormonal activity at the adrenal cortex while preserving central effects, which include increased expression of brain-derived neurotrophic factor and its receptor TrkB, and modulation of dopaminergic and serotonergic transmission. It is on the Russian essential medicines list for stroke and cognitive disorders.

Cerebrolysin vs Semax: common questions

What is the difference between Cerebrolysin and Semax?

Both are nootropic & neuro. Cerebrolysin: A porcine brain-derived peptide preparation used clinically across Europe and Asia for dementia and stroke. Semax: A heptapeptide ACTH fragment analog used in Russia for stroke and cognitive indications, with no corticotropic activity.

Which has stronger evidence, Cerebrolysin or Semax?

Cerebrolysin has the stronger evidence base (clinical trials, about 40 human studies) compared with Semax (preliminary human).

Are Cerebrolysin and Semax FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  2. PubChem compound record (CID 9811102) ↗ · structure, identifiers, synonyms
  3. CAS Registry Number 80714-61-0 ↗ · chemical identity

Published literature

  1. Cook AM, Michas M, Robbins B. Update on Neuroprotection after Traumatic Brain Injury.CNS Drugs 2025.PubMed 40087248 · doi:10.1007/s40263-025-01173-9
  2. Cui S, Chen N, Yang M, et al.. Cerebrolysin for vascular dementia.Cochrane Database Syst Rev 2019.PubMed 31710397 · doi:10.1002/14651858.CD008900.pub3
  3. Ziganshina LE, Abakumova T, Hoyle CH. Cerebrolysin for acute ischaemic stroke.Cochrane Database Syst Rev 2020.PubMed 32662068 · doi:10.1002/14651858.CD007026.pub6
  4. Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke.Cochrane Database Syst Rev 2017.PubMed 28430363 · doi:10.1002/14651858.CD007026.pub5
  5. Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke.Cochrane Database Syst Rev 2016.PubMed 27918088 · doi:10.1002/14651858.CD007026.pub4
  6. Ziganshina LE, Abakumova T. Cerebrolysin for acute ischaemic stroke.Cochrane Database Syst Rev 2015.PubMed 26083192 · doi:10.1002/14651858.CD007026.pub3
  7. Masserini F, Gendarini C, Baso G, et al.. Therapeutic strategies in vascular cognitive impairment: A systematic review and meta-analysis.Alzheimers Dement 2025.PubMed 41198594 · doi:10.1002/alz.70840
  8. Bogolepova AN. [Cognitive impairment in post-traumatic stress disorder].Zh Nevrol Psikhiatr Im S S Korsakova 2024.PubMed 38884432 · doi:10.17116/jnevro202412405169
  9. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  10. Tarasov VV, Kudryashov NV, Chubarev VN, et al.. Pharmacological Aspects of Neuro-Immune Interactions.Curr Pharm Des 2018.PubMed 28875850 · doi:10.2174/1381612823666170829135115
  11. Ilina AR, Popovich IG, Ryzhak GA, et al.. [Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease.].Adv Gerontol 2024.PubMed 38944767
  12. Sudakov KV. [Evolution of the stress concept].Vestn Ross Akad Med Nauk 2008.PubMed 19140465
  13. Gusev EI, Martynov MY, Kostenko EV, et al.. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke].Zh Nevrol Psikhiatr Im S S Korsakova 2018.PubMed 29798983 · doi:10.17116/jnevro20181183261-68
  14. Vyunova TV, Medvedeva EV, Andreeva LA, et al.. [POSSIBLE ROLE OF TRANSTHYRETIN IN THE BIOLOGICAL MECHANISM OF THE REGULATORY PEPTIDE NEUROPROTECTION.].Mol Gen Mikrobiol Virusol 2016.PubMed 30383932
  15. Giri S, Chandra P. Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases.Neuropeptides 2025.PubMed 41004910 · doi:10.1016/j.npep.2025.102563
  16. Spirin NN, Fedorov VN, Vdovichenko VP. [Place of oligopeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH in the therapy and rehabilitation of patients with ischemic stroke].Zh Nevrol Psikhiatr Im S S Korsakova 2024.PubMed 39166935 · doi:10.17116/jnevro202412408256

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.